Phase 1 N=87 A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors
Advanced Malignancies
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=60 Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers
Healthy Volunteers
Primary: Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC(0-t)) — 1330; 1340; 1020; 1500 hr·ng/mL
Phase 1 N=75 Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1
Influenza A Subtype H5N1 Infection
Primary: Immediate Reactions Occurring Within 60 Minutes of Administration of Any Dose — 0; 0; 0; 0 Participants
Phase 1 N=8 Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism
Autism Spectrum Disorder · Aggression · Irritability
Primary: Change From Baseline in Aberrant Behavior Checklist Irritability Subscale (ABC-I) — -12; -7 units on a scale — p=.44
Phase 1 N=60 Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers
QT Effects in Healthy Volunteers
Primary: Mean Change From Baseline in QTc Interval (Corrected by Friderica's Formula, dQTcF) Associated With Plasma Moxidectin Concentrations After a Single Dose — -5.1; -4.5…
Phase 1 N=73 Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress
Alcohol Use Disorders
Primary: Alcohol Craving — 2.89; 3.08 scores on a scale
Phase 1 N=60 Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers
Healthy Volunteers
Primary: Area Under the Plasma Concentration-Time Curve From Zero Time (Predose) to Time of Last Quantifiable Concentration (AUC(0-t)) — 1010; 1010; 965 ng·hr/mL — p=0.8826
Phase 1 N=24 A Study of LY3143753 and LY3185643 in Healthy Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 1 N=160 A Study of Galcanezumab in Healthy Participants.
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Galcanezumab — 31.5; 32.3 micrograms per milliliter (ug/mL)
Phase 1 N=28 A Study of Ixekizumab in Participants With Plaque Psoriasis
Psoriasis
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Cytochrome P450 (CYP450) Substrate-Midazolam — 4.56; 4.92; 4.83 nanogram per milliliter (ng/mL)
Phase 1 N=53 Study of MLN8237 in Participants With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Part A: Dose-normalized Cmax (Maximum Observed Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule…
Phase 1 N=32 Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects
Healthy
Primary: Cmax for Arm 1 (Lomitapide & EE/Noregestimate - Taken Together) — 1.03; 1.39; 2.96; 2.95 ng/mL
Phase 1 N=48 Staccato Prochlorperazine Thorough QT/QTc
Cardiotoxicity
Primary: Maximum Effect of Inhaled Prochlorperazine on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 5.493; 5.229 milliseconds
Phase 1 N=80 A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013)
Herpes Zoster
Primary: Geometric Mean Fold Rise (GMFR) of the VZV-specific Immune Responses Measured by VZV Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISPOT) — 4.34 Ratio — p=<0.001
Phase 1 N=30 Staccato Loxapine Pulmonary Safety in Healthy Volunteers
Healthy
Primary: The Largest Treatment Difference (Loxapine - Placebo) in Change in FEV1 From Baseline by Spirometry — -0.1042; -0.1025 liters